Personnel Information

写真a

SHIBA Kumiko


Job title

Assistant Professor

Graduating School 【 display / non-display

  • Tokyo Medical and Dental University, Faculty of Medicine, 2009.03, Graduated

Graduate School 【 display / non-display

  • Tokyo Medical and Dental University, Doctor's Course, 2018.03, Completed

Campus Career 【 display / non-display

  • 2014.04
    -
    2018.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Molecular Endocrinology and Metabolism, Graduate Student
  • 2018.04
    -
    2019.10
    Tokyo Medical and Dental University, Medical Hospital, Hospital Departments, Department of Internal Medicine, Diabetes, Endocrinology and Metabolism, Assistant Professor
  • 2018.04
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Molecular Endocrinology and Metabolism, Assistant Professor
  • 2019.11
    -
    2020.03
    Tokyo Medical and Dental University, Medical Hospital, Hospital Departments, Department of Internal Medicine, Diabetes, Endocrinology and Metabolism, Assistant Professor
  • 2020.04
    -
    2021.09
    Tokyo Medical and Dental University, Medical Hospital, Central Clinical Facilities, a, Assistant Professor
  • 2021.10
    -
    Now
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Integrated Facilities, Center for Personalized Medicine for Healthy Aging, Assistant Professor

▼display all

Research Areas 【 display / non-display

  • Metabolism and endocrinology

Qualification Acquired 【 display / non-display

  • Doctor

 

Published Papers & Misc 【 display / non-display

  1. Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh, Takayoshi Suganami, Yoshihiro Ogawa. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 2018.02; 8 (1): 2362. ( PubMed, DOI )

  2. Komiya Chikara, Tanaka Miyako, Tsuchiya Kyoichiro, Shimazu Noriko, Mori Kentaro, Furuke Shunsaku, Miyachi Yasutaka, Shiba Kumiko, Yamaguchi Shinobu, Ikeda Kenji, Ochi Kozue, Nakabayashi Kazuhiko, Hata Ken-ichiro, Itoh Michiko, Suganami Takayoshi, Ogawa Yoshihiro. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis SCIENTIFIC REPORTS. 2017.03; 7 44754. ( PubMed, DOI )

  3. Miyachi Yasutaka, Tsuchiya Kyoichiro, Komiya Chikara, Shiba Kumiko, Shimazu Noriko, Yamaguchi Shinobu, Deushi Michiyo, Osaka Mizuko, Inoue Kouji, Sato Yuta, Matsumoto Sayaka, Kikuta Junichi, Wake Kenjiro, Yoshida Masayuki, Ishii Masaru, Ogawa Yoshihiro. Roles for Cell-Cell Adhesion and Contact in Obesity- Induced Hepatic Myeloid Cell Accumulation and Glucose Intolerance CELL REPORTS. 2017.03; 18 (11): 2766-2779. ( PubMed, DOI )

  4. Chikara Komiya, Kyoichiro Tsuchiya, Kumiko Shiba, Yasutaka Miyachi, Shunsaku Furuke, Noriko Shimazu, Shinobu Yamaguchi, Kazuo Kanno, Yoshihiro Ogawa. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE. 2016.03; 11 (3): e0151511. ( PubMed, DOI )

  5. Miyachi Yasutaka, Tsuchiya Kyoichiro, Shiba Kumiko, Mori Kentaro, Komiya Chikara, Ogasawara Naomi, Ogawa Yoshihiro. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition SCIENTIFIC REPORTS. 2018.10; 8 (1): 16113. ( PubMed, DOI )

  6. Mori K, Tsuchiya K, Nakamura S, Miyachi Y, Shiba K, Ogawa Y, Kitamura K. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice. Cardiovascular diabetology. 2019.06; 18 (1): 83. ( PubMed, DOI )

  7. Nakano Y, Komiya C, Shimizu H, Mishima H, Shiba K, Tsujimoto K, Ikeda K, Kashimada K, Dateki S, Yoshiura KI, Ogawa Y, Yamada T. A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5. Endocrine journal. 2020.07; 67 (11): 1099-1105. ( PubMed, DOI )

  8. Fukuda T., Bouchi R., Asakawa M., Takeuchi T., Shiba K., Tsujimoto K., Komiya C., Yoshimoto T., Ogawa Y., Yamada T.. Sarcopenic obesity is associated with a faster decline in renal function in people with type 2 diabetes DIABETIC MEDICINE. 2020.01; 37 (1): 105-113. ( PubMed, DOI )

  9. Mori Kentaro, Tsuchiya Kyoichiro, Nakamura Suguru, Miyachi Yasutaka, Shiba Kumiko, Ogawa Yoshihiro, Kitamura Kenichiro. Deficiency of Melanocortin 4 Receptor Promotes Vascular Vulnerability in Mice DIABETES. 2018.07; 67 ( DOI )

▼display all

Conference Activities & Talks 【 display / non-display

  1. Mori Kentaro, Tsuchiya Kyoichiro, Nakamura Suguru, Miyachi Yasutaka, Shiba Kumiko, Ogawa Yoshihiro, Kitamura Kenichiro. マウスにおいてメラノコルチン4受容体の欠損は血管脆弱性を促進する(Deficiency of melanocortin 4 receptor promotes vascular vulnerability in mice). 日本内分泌学会雑誌 2018.04.01

  2. Mori Kentaro, Tsuchiya Kyoichiro, Nakamura Suguru, Miyachi Yasutaka, Shiba Kumiko, Ogawa Yoshihiro, Kitamura Kenichiro. マウスにおいてメラノコルチン4受容体の欠損は血管脆弱性を促進する(Deficiency of melanocortin 4 receptor promotes vascular vulnerability in mice). 日本内分泌学会雑誌 2018.04.01